Objective

To evaluate the quality of life of adult patients with hematologic cancer according to the modality of hematopoietic stem cell transplant during hospitalization stages.

Method

A quantitative, observational, longitudinal and analytical study with 55 adult participants diagnosed with hematologic cancer who underwent hematopoietic stem cell transplant between September 2013 and November 2015. Three instruments were used, one for sociodemographic and clinical characterization, and two instruments for quality of life assessment, as follows: the Quality Of Life Questionnaire - Core30 (QLQ-C30), version 3.0 in Portuguese developed by the European Organization Research Treatment of Cancer (EORTC) and the Functional Assessment Cancer Therapy- Bone Marrow Transplantation (FACT-BMT) questionnaire, version 4.0 in Portuguese developed by the Functional Assessment of Chronic Illness Therapy (FACIT), both validated for Brazil.

Result

The results showed the mean age for autologous hematopoietic stem cell transplant was 45 years, the prevalence of multiple myeloma diagnosis and for allogeneic stem cell transplant was 31 years, and leukemia was the predominant diagnosis. The quality of life assessment with both questionnaires and modalities showed a significant decrease in values in all domains evaluated, with predominance of worse scores in the pancytopenia period, except for the emotional function.

Conclusion

The present study concludes that hematopoietic stem cell transplant changes the quality of life during hospitalization for both transplant modalities. The promotion of interventions to improve patients’ quality of life by covering physical, emotional, social and functional domains is the nurses’ role.

        · resumen en Español | Portugués     · texto en Español | Inglés | Portugués     · Español ( pdf ) | Inglés ( pdf ) | Portugués ( pdf )